ClinicalTrials.gg
CompletedNCT05129683Updated Aug 3, 2023

Single Session of Anodal Cerebellar vs Cerebral Transcranial Direct Current Stimulation in Stroke Patients

An interventional study of Anodal tDCS cerebellar stimulation group and Anodal tDCS cerebral (M1) stimulation group in Stroke, sponsored by Riphah International University. Completed at 1 site in Pakistan. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-08-03.

Sponsored by Riphah International University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Study summary

To compare the effect of anodal cerebellar transcranial direct current stimulation (ctDCS) vs anodal cerebral direct current stimulation on balance, mobility and cognition in stroke patients in stroke patients

02

Conditions studied

  • Stroke

Browse trials for

Keywords

  • Transcranial Direct Current Stimulation
  • Anodal Cerebral
03

In context

Stroke

7,443 studies on the registry are indexed under Stroke; 2,012 are open to participants now.

This study's enrollment of 66 is above the median of 50 across 5,482 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

Riphah International University is the lead sponsor of 2,176 studies on the registry; 637 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ability to give written consent.
  • Able to walk unassisted
  • Functional status allowing the participants to participate in the balance training.
  • Score 6 or above on Johns Hopkins fall risk assessment tool

Exclusion criteria

Exclusion Criteria:

  • Neurological diseases, such as Parkinson, Alzheimer
  • Any history of psychological illnesses
  • Receipt of electrotherapy that might affect the nervous system in the two weeks prior to the study
  • Cerebellar disorders
  • use of any sedative medicines in the two days prior to the study
  • any symptoms of amnesia and depression;
  • Memory disorders with scores below 21 on the Mini Mental Status Examination test
  • Any signs of severe motor disorders in the lower extremity which cause any movement limitation or deformity
  • Any signs of radiculopathy or root lumbar spinal cord involvement
  • Any visual or auditory impairment, or vertigo reports
  • Use of a heart rate regulator
  • Any structural deformities in the lower extremities or the spine
  • Any abnormalities in the vestibular system
  • History of recent fracture
  • Inability to move without assistance
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Anodal tDCS cerebellar stimulation group:

    Anodal tDCS cerebellar stimulation

    Other: Anodal tDCS cerebellar stimulation group

  • Experimental
    Anodal tDCS cerebral (M1) stimulation group:

    Anodal tDCS cerebral (M1) stimulation

    Other: Anodal tDCS cerebral (M1) stimulation group

  • Sham comparator
    Sham Group

    Sham: Single-session a-tDCS (2 mA, 20 min),

    Other: sham group

Interventions

  • OtherAnodal tDCS cerebellar stimulation group

    Single-session atDCS (2 mA, 20 min). The active (anode) and the returning (cathode) electrodes will be placed bilaterally over the cerebellum (1 -2 cm below inion of occipital bone) and the right buccinator muscle, respectively Xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins will also be given

  • OtherAnodal tDCS cerebral (M1) stimulation group

    single session a-tDCS (2 mA, 20 min), the anode will be positioned over the lesioned M1 (C3, International 10-20 system) and the cathode would be located over the supraorbital area. xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.

  • Othersham group

    single session a-tDCS (2 mA, 20 min), Sham tDCS followed a similar protocol as Anodal tDCS cerebral (M1) stimulation and arrangement but stimulation for 30 s, after which the current was ramped-down and turned off for the rest of the treatment. xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.

06

What researchers measure

Primary outcomes

  1. Changes from the base line, Berg balance scale

    Changes from the base line, Immediately after Intervention and then again after 1 hour. The Berg balance scale (BBS) is used to assess the participant's ability to retain stability. The BBS is a widely used test for the assessment of elderly population with impairment of balance and individuals with neurological disorder while sitting, standing, and transferring. This test included both static and dynamic type task. The BBS uses a five-point ordinal scale ranging from 0 (disability) to 4(complete independent performance) and consists of 14 components; the maximum score is 56 points. The scale has been shown to be reliable and valid in stroke patients. A cut-off score of 45 points is used for fall prediction. The BBS involves 14 tasks; a total score of 56. Equipment required for this test were a stop watch or watch with a second's hand and a ruler or other indicator of 2, 5, and 10 inches.

    Time frame: Immediately after Intervention and then again after 1 hour.

  2. Timed Up and Go test

    Changes from the base line, Immediately after Intervention and then again after 1 hour. The Timed Up and Go (TUG) test was designed for the evaluation of balance and Measures mobility in people who are able to walk on their own (assistive device permitted) to find out the risk of fall . The subjects will be required to stand up from a chair, walk 3 m, turn around, return to the chair, and sit down. The time taken to complete this task will be measured. The test will be informed three times. The time required to complete this task will be measured from a stopwatch. The average values from 3 trials, with 1-min rest between each trial, were used for data analysis.

    Time frame: Immediately after Intervention and then again after 1 hour.

  3. Balance Evaluation Systems Test

    Changes from the base line, Immediately after Intervention and then again after 1 hour.. Balance Evaluation Systems Test (BESTest) is a 36-item assessment of balance impairments across 6 postural control contexts. Total score of 108 points total, calculated in to a percentage score (0-100%). Also total sub-scores exist for each above listed system. Item-level scores range from 0 (severe impairment) to 3 (no impairment)

    Time frame: Immediately after Intervention and then again after 1 hour.

Secondary outcomes

  1. Montreal cognitive Scale

    Changes from the base line, Immediately after Intervention and then again after 1 hour. The tool used for cognitive impairment is Montreal Cognitive Assessment (MoCA). As there is not at all, fairly effective measuring tool for the early diagnosis of cognitive impairments. MoCA is a successful screening test used for the screening of mild cognitive impairment. Scores of MoCA ranges from 0-30.Interpretation of MoCA indicates that score of 26 and above normal, 18 -25 score indicates low cognitive impairments, 10 -18 score considered normal or moderate cognitive impairment while greater than 10 is considered to be severe cognitive impairments.

    Time frame: 1 hour

  2. tDCS Adverse Effects Questionnaire :

    Changes from the base line, Immediately after Intervention and then again after 1 hour.. Transcranial Direct-Current Stimulation (tDCS) adverse effects questionaire: Do you experience any of the following symptoms or side- effects? Headache, Neck pain, Scalp pain, Tingling, Itching, Burning sensation, Skin redness, Sleepiness, Trouble concentrating, Acute mood change, Others (specify) for each symptom patient can give value (1-4) (1, absent; 2,mild; 3, moderate; 4, severe) If present: Is this related to tDCS? (1, none ; 2, remote; 3, possible; 4, probable; 5, definite)

    Time frame: Immediately after Intervention and then again after 1 hour.

  3. 6 min walk test: Distance (meters)

    Changes from the base line, Immediately after Intervention and then again after 1 hour. 6 min walk test was used to measure Functional capacity. It is a sub maximal exercise test which can aid in assessing functional capacity of patients with cardiopulmonary diseases, in this test we find out the maximum distance in meters which an individual covers in 6 min without any support.

    Time frame: Immediately after Intervention and then again after 1 hour.

  4. Timed 25-Foot Walk test

    Changes from the base line, Immediately after Intervention and then again after 1 hour. Timed 25-Foot Walk (T25-FW) test is a quantitative mobility and leg function performance test based on a timed 25-walk. Two trials will be given to the patient and time will be noted in seconds

    Time frame: Immediately after Intervention and then again after 1 hour.

  5. Johns Hopkins fall risk assessment Tool

    Changes from the base line, Immediately after Intervention and then again after 1 hour. Risk of falling was assessed using the Johns Hopkins Fall Risk Assessment score 13,14 ; a score of less than 6 is considered low risk, 6 to 13 is considered moderate risk, and greater than 13 is considered high risk.

    Time frame: Immediately after Intervention and then again after 1 hour.

  6. Mini mental state examination (MMSE)

    Changes from the base line, Immediately after Intervention and then again after 1 hour. Mini mental state examination (MMSE): used to screen for cognitive impairment in elderly. The maximum MMSE score is 30 points. A score of 20 to 24 suggests mild dementia, 13 to 20 suggests moderate dementia, and less than 12 indicates severe dementia.

    Time frame: Immediately after Intervention and then again after 1 hour.

07

Study locations

1 site
  • Akbar Hospital, Gujrat
    Dhok Gujra, Punjab Province 50010, Pakistan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Sep 2022, 11 months.

Of 2,859 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's 11 months is below that.

Counting every sponsor, half of 2,988 studies reached it within 23 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2021
First posted
Nov 22, 2021
StartActual
Oct 5, 2021
Primary completionActual
Sep 30, 2022
CompletionActual
Sep 30, 2022
Last update
Aug 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05129683
Responsible party
Sponsor
First posted
Nov 22, 2021
Start date
Oct 5, 2021
Primary completion
Sep 30, 2022
Completion
Sep 30, 2022
Last update
Aug 3, 2023

Study contacts

Arshad Nawaz Malik, PhD
principal investigator · Riphah International University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion